Navinci Diagnostics

Spatial Proteomics

Navinci has a proud history as developers of the first commercial in situ Proximity Ligation Assays. The Proximity Ligation Technology can be used to monitor interactions or modifications of endogenous proteins directly in individual cells and tissues, to reveal the cellular and molecular architecture and its response to disturbances.

Founded 2004
SMA Investment 2022
CEO Agata Zieba-Wicher
Chairperson Eva Pisa
Head Offices Uppsala, Sweden
SMA Representation Maria Tell (board member), Ludvig Wendel (board observer)